Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study

Q: How did bucillamine perform versus N-acetylcysteine (NAC) in the DRDC nerve-agent study for RVVTF?

According to Revive Therapeutics, bucillamine appeared comparable to NAC in preserving hippocampal GABA receptor post-synaptic density in the animal model. Both treatments showed preservation versus controls, while pulmonary hemorrhage was observed only in the NAC-treated group, not in the bucillamine-treated animals.

Q: What safety observations were reported for bucillamine in the DRDC nerve-agent research with RVVTF?

The study reported no pulmonary hemorrhage in the bucillamine-treated group, while such hemorrhage occurred in the NAC-treated group. According to Revive Therapeutics, no cerebral hemorrhage was observed in either group, and seizure activity and other clinical effects were similar across all study arms.

Q: What are the next steps for bucillamine nerve-agent research with DRDC and Revive Therapeutics (RVVTF)?

Defence Research and Development Canada plans additional confirmatory studies on bucillamine starting in Q4-2026. According to Revive Therapeutics, future research will examine brain injury, oxidative stress, response to standard treatments and respiratory function, potentially informing development and collaboration opportunities in biodefence.

Q: How could the bucillamine nerve-agent study impact Revive Therapeutics’ biodefence strategy?

The positive DRDC findings provide a scientific basis for further evaluation of bucillamine with established nerve-agent treatments. According to Revive Therapeutics, these results may help the company assess potential development, funding and collaboration opportunities with government, defence and other strategic organizations in biodefence.

Rhea-AI Impact

(Very High)

Rhea-AI Sentiment

(Positive)

Rhea-AI Summary

Revive Therapeutics (OTCQB:RVVTF) reported positive results from a Defence Research and Development Canada (DRDC) study evaluating bucillamine in an animal model of nerve-agent exposure. The study compared bucillamine to N-acetylcysteine (NAC), examining clinical signs, seizure activity and preservation of hippocampal GABA receptor post-synaptic density.

Animals pretreated with bucillamine or NAC both showed preserved GABA receptor post-synaptic density versus controls, with bucillamine appearing comparable to NAC on this endpoint. No pulmonary hemorrhage was observed in the bucillamine group, while it was observed in the NAC group; no cerebral hemorrhage occurred in either group. DRDC plans additional confirmatory bucillamine studies starting in Q4-2026, which may support Revive’s efforts to pursue development, funding and collaboration opportunities in biodefence and pandemic preparedness.

Positive

Comparable efficacy to NAC on hippocampal GABA receptor preservation in an animal nerve-agent model
No pulmonary hemorrhage observed in bucillamine-treated animals versus presence in the NAC-treated group
Planned confirmatory studies by DRDC on bucillamine beginning in Q4-2026

Negative

None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

08/12/2026 - 07:55 AM

TORONTO, ON / ACCESS Newswire / August 12, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today announced positive results from a research study conducted by Defence Research and Development Canada - Suffield Research Centre ("DRDC") evaluating bucillamine in an established animal model of nerve-agent exposure.

The study compared bucillamine with N-acetylcysteine ("NAC"), an antioxidant previously evaluated in this research model. The objective was to examine clinical signs, seizure activity and the preservation of GABA receptor signaling in the brain following exposure.

Animals pretreated with either bucillamine or NAC demonstrated preservation of hippocampal GABA receptor post-synaptic density compared with control animals. Bucillamine appeared comparable to NAC on this measured endpoint. All study groups displayed similar signs of seizure activity and other clinical effects associated with exposure.

Importantly, no pulmonary hemorrhage was observed in the bucillamine-treated group, whereas it was observed in the NAC-treated group. No signs of cerebral hemorrhage were observed in either group.

"The DRDC research study provides a scientific basis for continuing to evaluate bucillamine in combination with established treatments for nerve-agent exposure," said Michael Frank, Chief Executive Officer of Revive. "Bucillamine demonstrated preservation of the measured GABA receptor endpoint comparable to NAC, while pulmonary hemorrhage observed in the NAC-treated group was not observed in the bucillamine-treated group. These findings support our broader objective of evaluating bucillamine's potential role in biodefence and pandemic preparedness, and we intend to explore further related opportunities with government, defence, and other strategic organizations."

DRDC will continue its research on bucillamine through additional confirmatory studies scheduled to begin in Q4-2026. Additional research will evaluate its potential effects on brain injury, oxidative stress, response to standard treatment and respiratory function.

In addition, the current research findings and further research may help Revive evaluate potential development, funding, and collaboration opportunities with government, defence, and strategic organizations.

About Revive Therapeutics Ltd.

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness. For more information, visit www.revivethera.com.

For more information, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1-888-901-0036
Email: mfrank@revivethera.com
Website: www.revivethera.com

SOURCE: Revive Therapeutics Ltd.

View the original press release on ACCESS Newswire

FAQ

What did Revive Therapeutics (RVVTF) announce about bucillamine on August 12, 2026?

Revive Therapeutics announced positive preclinical results for bucillamine from a Defence Research and Development Canada study in an animal nerve-agent exposure model. According to Revive, bucillamine preserved a key GABA receptor endpoint and showed no pulmonary hemorrhage, unlike the N-acetylcysteine (NAC) comparison group.

How did bucillamine perform versus N-acetylcysteine (NAC) in the DRDC nerve-agent study for RVVTF?

According to Revive Therapeutics, bucillamine appeared comparable to NAC in preserving hippocampal GABA receptor post-synaptic density in the animal model. Both treatments showed preservation versus controls, while pulmonary hemorrhage was observed only in the NAC-treated group, not in the bucillamine-treated animals.

What safety observations were reported for bucillamine in the DRDC nerve-agent research with RVVTF?

The study reported no pulmonary hemorrhage in the bucillamine-treated group, while such hemorrhage occurred in the NAC-treated group. According to Revive Therapeutics, no cerebral hemorrhage was observed in either group, and seizure activity and other clinical effects were similar across all study arms.

What are the next steps for bucillamine nerve-agent research with DRDC and Revive Therapeutics (RVVTF)?

Defence Research and Development Canada plans additional confirmatory studies on bucillamine starting in Q4-2026. According to Revive Therapeutics, future research will examine brain injury, oxidative stress, response to standard treatments and respiratory function, potentially informing development and collaboration opportunities in biodefence.

How could the bucillamine nerve-agent study impact Revive Therapeutics’ biodefence strategy?

The positive DRDC findings provide a scientific basis for further evaluation of bucillamine with established nerve-agent treatments. According to Revive Therapeutics, these results may help the company assess potential development, funding and collaboration opportunities with government, defence and other strategic organizations in biodefence.